Skip to main content

Advertisement

SpringerLink
Log in

Expression of Cyclooxygenase-2 in Squamous Cell Carcinoma and Keratoacanthoma and its Clinical Significance

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

Cyclooxygenase (COX), also known as prostaglandin endoperoxide synthase, catalyzes the conversion of arachidonic acid to prostanoids. There are two different isoforms of COX, referred to as COX-1 and COX-2. Overexpression of COX-2 has been demonstrated in various neoplasms. In this study, we plan to utilize COX-2 in understanding the difference of squamous cell carcinoma and keratoacanthoma which have many similarities in both morphological and histological features. The objective of this study is to study the expression of COX-2 in squamous cell carcinoma and keratoacanthoma and to discuss its clinical significance. The expression of COX-2 in 55 cases of skin tumors (including 30 specimens of squamous cell carcinoma, 25 specimens of keratoacanthoma) and 20 normal skin tissues was detected by immunohistochemical technique. The positive expression of COX-2 was found in 73.3 % (22/30) of squamous cell carcinoma and 12 % (3/25) of keratoacanthoma cases. The positive expression rate of COX-2 in 55 skin tumors (45.5 %) was significantly higher than that in normal skin tissues (5 %) (χ 2 = 10.598 %, P < 0.05). The expression of COX-2 in squamous cell carcinoma (73.3 %) was significantly higher than that in keratoacanthoma (12 %) (χ 2 = 20.69, P < 0.05). COX-2 overexpression may play a potential role in the pathogenesis of skin tumors. The positive expression rate of COX-2 is associated with the malignant degree of the tumor, and also it may help differentiating squamous cell carcinoma from keratoacanthoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kanaoka, S., Takai, T., & Yoshida, K. (2007). Cyclooxygenase-2 and tumor biology. Advances in Clinical Chemistry, 43, 59–78.

    CAS  PubMed  Google Scholar 

  2. Harris, R. E., Beebe-Donk, J., Doss, H., & Burr, D. D. (2005). Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade. Oncology Reports, 13(4), 559–583.

    CAS  PubMed  Google Scholar 

  3. Vainio, H., & Morgan, G. (1999). Non-steroidal anti-inflammatory drugs and chemo prevention of cancer. Annales chirurgiae et gynaecologiae, 89(3), 173–176.

    Google Scholar 

  4. Thun, M. J., Henley, S. J., & Patrono, C. (2002). Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic and clinical issues. Journal of National Cancer Institution, 94, 252–266.

    Article  CAS  Google Scholar 

  5. Marks, F., Furstenberger, G., Neufang, G., & Müller-Decker, K. (2003). Mouse skin as a model for cancer chemoprevention by nonsteroidal anti-inflammatory drugs. Recent Results Cancer Res, 163, 46–57.

    CAS  PubMed  Google Scholar 

  6. Cahlin, C., Gelin, J., Andersson, M., Lönnroth, C., & Lundholm, K. (2005). The effects of non-selective, preferential-selective and selective COX-inhibitors on the growth of experimental and human tumors in mice related to prostanoid receptors. International Journal of Oncology, 27(4), 913–923.

    CAS  PubMed  Google Scholar 

  7. Davies, G. L. (2003). Cyclooxygenase-2 and chemoprevention of breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 86, 495–499.

    Article  CAS  PubMed  Google Scholar 

  8. Jiang, X. H., & Wong, B. C. (2003). Cyclooxygenase-2 inhibition and gastric cancer. Current Pharmaceutical Design, 9, 2281–2288.

    Article  CAS  PubMed  Google Scholar 

  9. Hong, L., Zhizheng, G., Wenzhong, L., Xiaoyu, C., Yanshen, P., & Shudong, X. (2007). Expression on COX-2 in colonal disease. Journal of Gastroenterol, 5, 148–160.

  10. Ali, F. R., Che, M. X., Ibrahim, K. I., Malone, J. M., Morris, R., Lawrence, W. D., & Munkarah, A. R. (2003). The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer, 98(7), 1423–1429.

    Article  Google Scholar 

  11. Crosby, C. G., & DuBois, R. N. (2003). The cyclooxygenase-2 pathway as a target for treatment or prevention of cancer. Expert Opinion on Emerging Drugs, 8, 1–7.

    Article  CAS  PubMed  Google Scholar 

  12. Van Dross, R. T., Hong, X., & Pelling, J. C. (2005). Inhibition of TPA-induced cyclooxygenase-2 (COX-2) expression by apigenin through down regulation of Akt signal transduction in human keratinocytes. Molecular Carcinogenesis, 44, 83–91.

    Article  PubMed  Google Scholar 

  13. Liao, Z., Mason, K. A., & Milas, L. (2007). Cyclooxygenase-2 and its inhibition in cancer: Is there a role? Drugs, 67(6), 821–845.

    Article  CAS  PubMed  Google Scholar 

  14. Harris, R. E., Beebe-Donk, J., & Alshafie, G. A. (2006). Reduction in the risk of human breast cancer by selective cyclonxygenase-2 (COX-2) inhibitors. BMC Cancer, 6, 27.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Maran, E. M. (2002). Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. Journal of Environmental Pathology, Toxicology and Oncology, 21(2), 193–201.

    Google Scholar 

  16. An, K. P., Athar, M., Tang, X., Katiyar, S. K., Russo, J., Beech, J., et al. (2002). Cycloogenase-2 expression in murine and human nonmelanoma skin cancers: Implications for therapeutic approaches. Journal of Photochemistry and Photobiology, 76, 73–80.

    Article  CAS  Google Scholar 

  17. Saha, P., Mandal, S., Das, A., & Das, S. (2006). Amarogentin can reduce hyperproliferation by downregulation of Cox-II and upregulation of apoptosis in mouse skin carcinogenesis model. Journal of Cancer Letters, 244(2), 252–259.

    Article  CAS  Google Scholar 

  18. Aziz, M. H., Wheeler, D. L., Bhamb, B., & Verma, A. K. (2006). Protein kinase C delta overexpressing transgenic mice are resistant to chemically but not to UV radiation-induced development of squamous cell carcinomas: A possible link to specific cytokines and cyclooxygenase-2. Journal of Cancer Research, 66(2), 713–722.

    Article  CAS  Google Scholar 

  19. Nijsten, T., Colpaert, C. G., Vermeulen, P. B., Harris, A. L., Van, M. E., & Lambert, J. (2004). Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: A paired immunohistochemical study of 35 cases. British Journal of Dermatology, 151(4), 837–845.

    Article  CAS  PubMed  Google Scholar 

  20. Kim, K. H., Park, E. J., Seo, Y. J., Cho, H. S., Kim, C. W., Kim, K. J., & Park, H. R. (2006). Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors. Journal of Dermatology, 33, 319–325.

    Article  CAS  PubMed  Google Scholar 

  21. Leong, J., Hughes-Fulford, M., Rakhlin, N., Habib, A., Maclouf, J., & Goldyne, M. E. (1996). Cyclooxygenases in human and mouse skin and cultured human keratinocytes: Association of COX-2 expression with human keratinocyte differentiation. Experimental Cell Research, 224, 79–87.

    Article  CAS  PubMed  Google Scholar 

  22. Kagoura, M., Toyoda, M., Matsui, C., & Morohashi, M. (2001). Immunohistochemical expression of cyclooxygenase-2 in skin cancers. Journal of Cutan Pathology, 28(6), 298–302.

    Article  CAS  Google Scholar 

  23. Xinhong, G., Ping, T., Gangwen, H., Lingshen, W., & Xuejun, Z. (2004). Research on expression of desmogleins 1 and E-cadherin in squamous cell carcinoma and keratoacanthoma. Journal of Clinical Dermatology, 33, 166–167.

  24. Krunic, A. L., Garrod, D. R., Madani, S., Buchanan, M. D., & Clark, R. E. (1998). Immunohistochemical staining for desmogleins 1 and 2 in keratinocytic neoplasms with squamous phenotype; actinic keratosis, keratoacanthoma and squamous cell carcinoma of skin. British Journal of Cancer, 77, 1275–1279.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Putti, T. C., Teh, M., & Lee, Y. S. (2004). Biological behavior of keratoacanthoma and squamous cell carcinoma: Telomerase activity and COX-2 as potential markers. Modern Pathology, 17, 468–475.

    Article  CAS  PubMed  Google Scholar 

  26. Gallo, O., Schiavone, N., Papucci, L., Sardi, I., Magnelli, L., Franchi, A., et al. (2003). Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma. American Journal of Pathology, 163, 723–732.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology and Venereology, The Wuxi Second Affiliated Hospital of Nanjing Medical University, Wuxi, 214002, China

    Hai-Kang Hua, Cheng Jin, Li-Jia Yang, Shi-Qin Tao & Xiao-Hong Zhu

Authors
  1. Hai-Kang Hua
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cheng Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li-Jia Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shi-Qin Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiao-Hong Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hai-Kang Hua.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hua, HK., Jin, C., Yang, LJ. et al. Expression of Cyclooxygenase-2 in Squamous Cell Carcinoma and Keratoacanthoma and its Clinical Significance. Cell Biochem Biophys 72, 475–480 (2015). https://doi.org/10.1007/s12013-014-0490-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-014-0490-7

Keywords

Search

Navigation